Story of Nanologica
Story of nanologica
Nanologica is a Swedish life science Group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances.
Nanologica AB (publ) was founded in 2004 and stems from research within material sciences on the synthesis, analysis, and characterization of new porous materials. With a foundation in materials science and nanotechnology, the company has developed an expertise in chromatography. Today, Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, and has developed a broad product range of chromatography media beyond silica.
Nanologica’s products are used to purify pharmaceuticals during production using a technique called preparative chromatography. Our silica-based purification media for preparative chromatography, NLAB Saga®, has been especially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues.
Through proprietary production methods, we create world-class products that can purify more effectively and that last longer. This can reduce production costs and increase productivity for pharmaceutical manufacturers, making staple medicines available to more patients. Our mission is to increase the availability of cost-effective drugs, enabling more patients around the world access to vital treatments for diabetes and obesity, for example.
In 2026, Nanologica AB (publ) acquired Syntagon AB, a Swedish CDMO (contract developing and manufacturing organization) of drug molecules. Syntagon offers services in API development, GMP manufacturing, and advanced analysis and purification.
Founded in 1998 in Södertälje, Sweden, Syntagon has more than two decades of experience in developing and manufacturing complex drug substances.
The plant in Södertälje specializes in API development and API production with the capacity to take APIs from preclinical to clinical studies and further into commercial manufacturing.
By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, the Nanologica Group provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances.
Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines.
Nanologica has a proven ability to identify and develop strong product concepts. To create the best possible preconditions for development and growth, Nanologica has at times chosen to spin out business concepts into separate entities. The first was Exeger (solar cells for indoor use) in 2011, and the second was Sigrid Therapeutics (treatment for obesity) in 2014.
In 2015 the company’s share (NICA) was listed for trade on Spotlight Stock Market and since 2022 the share is listed on Nasdaq Stockholm Main Market.
